SAN DIEGO, March 15, 2018 /PRNewswire/ -- OncoSec
Medical Incorporated (OncoSec) (NASDAQ: ONCS), a company developing
intratumoral cancer immunotherapies, today announced that clinical
and immunological data from its OMS-I140 clinical trial
of ImmunoPulse® IL-12 in patients with metastatic Triple Negative
Breast Cancer (TNBC) has been selected as an oral poster
presentation at the upcoming American Association of Cancer
Research (AACR) Annual Meeting, in Chicago, IL on April
14-18, 2018.
Details of the oral poster presentation are as follows:
Abstract Title: Intratumoral plasmid IL-12 and
electroporation in pre-treated inoperable locally advanced
or recurrent triple-negative breast cancer
(TNBC) (Abstract #CT022)
Session Title: Phase I Clinical Trials 1
Date and Time: Sunday, April 15,
2018 1:00 PM - 5:00 PM EST
Location: McCormick Place South, Hall A, Poster Section
42
Further details on the poster presentation will be provided in
upcoming Company communications. For more information about this
conference, please visit: www.aacr.org.
About OncoSec Medical Incorporated
OncoSec is a
biotechnology company developing DNA-based intratumoral
immunotherapies with an investigational technology,
ImmunoPulse®, for the treatment of cancer. ImmunoPulse
is designed to enhance the local delivery and uptake of DNA-based
immune-targeting agents, such as plasmid encoded IL-12
(tavokinogene telseplasmid or "tavo"). In Phase 1 and 2 clinical
trials, ImmunoPulse® IL-12 has demonstrated a favorable
safety profile, evidence of anti-tumor activity in the treatment of
various solid tumors, and the potential to reach beyond the site of
local treatment to initiate a systemic immune response. OncoSec's
lead program, ImmunoPulse IL-12, is currently in clinical
development for metastatic melanoma and triple-negative breast
cancer. The program's current focus is on the significant unmet
medical need in patients with melanoma who are refractory or have
relapsed on anti-PD-1 therapies. In addition to tavo, the Company
is also identifying and developing new immune-targeting agents for
use with the ImmunoPulse platform. For more information, please
visit www.oncosec.com.
CONTACT
Investor Relations:
Stern Investor Relations
Will O'Connor
Phone: (212) 362-1200
will@sternir.com
Media Relations:
Janine McCargo / David Schemelia
Tiberend Strategic Advisors, Inc.
Phone: 212-827-0020
jmccargo@tiberend.com
dschemelia@tiberend.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/oncosecs-intratumoral-il-12-in-metastatic-triple-negative-breast-cancer-tnbc-selected-for-oral-poster-presentation-at-the-american-association-for-cancer-research-aacr-annual-meeting-2018-300614491.html
SOURCE OncoSec Medical Incorporated